Abstract
You have accessJournal of UrologyKidney Cancer: Localized (III)1 Apr 20131459 EXCELLENT LONG TERM (5.5 YEAR) OUTCOME OF LAPAROSCOPIC AND PERCUTANEOUS COMPUTER TOMOGRAPHY GUIDED RADIOFREQUENCY ABLATION OF RENAL MASSES WITH REAL-TIME TEMPERATURE MONITORING Gideon Lorber, Arturo Castro, Vladislav Gorbatiy, Mehul Doshi, and Reymond Leveillee Gideon LorberGideon Lorber Miami, FL More articles by this author , Arturo CastroArturo Castro Miami, FL More articles by this author , Vladislav GorbatiyVladislav Gorbatiy Miami, FL More articles by this author , Mehul DoshiMehul Doshi Miami, FL More articles by this author , and Reymond LeveilleeReymond Leveillee Miami, FL More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2813AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The small number of studies reporting long term followup (FU) of patients treated with radiofrequency ablation (RFA) of renal masses hampers comparison of this modality to well established long term FU series of patients treated surgically. In this study we report long term oncological results of patients treated with RFA of renal masses in a single institution. METHODS We reviewed our prospectively collected database of patients with solid enhancing renal masses treated between November 2001 and October 2012 with laparoscopic (LRFA) or computed tomography (CT) guided percutaneous RFA (CTRFA). All treatments were performed with real-time temperature monitoring to ensure target ablation temperature was adequately reached and did not overheat adjacent structures. Inclusion criteria consisted of patients with a FU longer than 48 months. FU consisted of physical examination, serum creatinine measurement and series of interval enhanced radiographic imaging (CT or MRI). We reviewed the overall complication rate and degree as well as the overall survival (OS), cancer specific survival (CSS) and recurrence free survival (RFS). RESULTS Out of 434 RFA cases, a total of 77 treatments in 67 patients met the inclusion criteria. Of these, 42 masses were treated with CTRFA and 35 with LRFA. The mean FU interval was 65.4 months (48.5-120.2) and the mean renal mass size was 2.5 cm (0.8-4.8). Of the 77 treatments, 56 (73%) had biopsy confirmed renal cell carcinoma. The reminder had benign or undetermined pathology while 3 had no biopsy. Overall there were 6 local recurrences and one case of distant metastases with no local recurrence. Complication rate was 27% of which 76% where Clavien-Dindo grade I, 19% grade II and 5% (1 case) grade IVa. The average pre and post op creatinine were 1.07 and 1.16 respectively. The OS was 96%, CSS was 96% and RFS was 93%. CONCLUSIONS When performed on selected patients, while monitoring real-time temperatures, RFA offers favorable long term oncological outcomes approaching those reported for partial nephrectomy. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e598 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Gideon Lorber Miami, FL More articles by this author Arturo Castro Miami, FL More articles by this author Vladislav Gorbatiy Miami, FL More articles by this author Mehul Doshi Miami, FL More articles by this author Reymond Leveillee Miami, FL More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.